 | • レポートコード：QYR2104Z2000 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、152ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、非小細胞肺がん治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ラジオ波焼灼療法（RFA）、放射線療法、化学療法、標的療法、免疫療法）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・非小細胞肺がん治療薬の市場動向 ・企業の競争状況、市場シェア ・非小細胞肺がん治療薬の種類別市場規模（ラジオ波焼灼療法（RFA）、放射線療法、化学療法、標的療法、免疫療法） ・非小細胞肺がん治療薬の用途別市場規模（病院、診療所、その他） ・非小細胞肺がん治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・非小細胞肺がん治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・非小細胞肺がん治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非小細胞肺がん治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・非小細胞肺がん治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bristol-Myers Squibb、GlaxoSmithKline、Menarini、Sanofi、Ziopharm Oncology、Alchemia、Amgen、Apotex、BioMarin Pharmaceutical、CellAct Pharma、Cerulean Pharma、Cipla、Cornerstone Pharmaceuticals、Curis、CytRx、Eli Lilly、Exelixis、Fresenius Kabi、Genentech、Hikma Pharmaceuticals、Hospira、Intas Pharmaceuticals、Karyopharm Therapeutics、Kyowa Hakko Kirin、Ligand Pharmaceuticals） ・結論 |
Market Analysis and Insights: Global Drugs for Non-small Cell Lung Cancer Market
The global Drugs for Non-small Cell Lung Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Non-small Cell Lung Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Non-small Cell Lung Cancer market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Non-small Cell Lung Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Non-small Cell Lung Cancer market.
Global Drugs for Non-small Cell Lung Cancer Scope and Market Size
Drugs for Non-small Cell Lung Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Non-small Cell Lung Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Segment by Application
Hospitals
Clinics
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
Sanofi
Ziopharm Oncology
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Non-small Cell Lung Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Radiofrequency Ablation (RFA)
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Targeted Therapies
1.2.6 Immunotherapy
1.3 Market by Application
1.3.1 Global Drugs for Non-small Cell Lung Cancer Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Non-small Cell Lung Cancer Market Perspective (2016-2027)
2.2 Drugs for Non-small Cell Lung Cancer Growth Trends by Regions
2.2.1 Drugs for Non-small Cell Lung Cancer Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Drugs for Non-small Cell Lung Cancer Historic Market Share by Regions (2016-2021)
2.2.3 Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Regions (2022-2027)
2.3 Drugs for Non-small Cell Lung Cancer Industry Dynamic
2.3.1 Drugs for Non-small Cell Lung Cancer Market Trends
2.3.2 Drugs for Non-small Cell Lung Cancer Market Drivers
2.3.3 Drugs for Non-small Cell Lung Cancer Market Challenges
2.3.4 Drugs for Non-small Cell Lung Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Revenue
3.1.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Revenue (2016-2021)
3.1.2 Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Players (2016-2021)
3.2 Global Drugs for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Drugs for Non-small Cell Lung Cancer Revenue
3.4 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio
3.4.1 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Non-small Cell Lung Cancer Revenue in 2020
3.5 Drugs for Non-small Cell Lung Cancer Key Players Head office and Area Served
3.6 Key Players Drugs for Non-small Cell Lung Cancer Product Solution and Service
3.7 Date of Enter into Drugs for Non-small Cell Lung Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Non-small Cell Lung Cancer Breakdown Data by Type
4.1 Global Drugs for Non-small Cell Lung Cancer Historic Market Size by Type (2016-2021)
4.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Type (2022-2027)
5 Drugs for Non-small Cell Lung Cancer Breakdown Data by Application
5.1 Global Drugs for Non-small Cell Lung Cancer Historic Market Size by Application (2016-2021)
5.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Drugs for Non-small Cell Lung Cancer Market Size (2016-2027)
6.2 North America Drugs for Non-small Cell Lung Cancer Market Size by Type
6.2.1 North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021)
6.2.2 North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027)
6.2.3 North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2027)
6.3 North America Drugs for Non-small Cell Lung Cancer Market Size by Application
6.3.1 North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021)
6.3.2 North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027)
6.3.3 North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2027)
6.4 North America Drugs for Non-small Cell Lung Cancer Market Size by Country
6.4.1 North America Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021)
6.4.2 North America Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Drugs for Non-small Cell Lung Cancer Market Size (2016-2027)
7.2 Europe Drugs for Non-small Cell Lung Cancer Market Size by Type
7.2.1 Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021)
7.2.2 Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027)
7.2.3 Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2027)
7.3 Europe Drugs for Non-small Cell Lung Cancer Market Size by Application
7.3.1 Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021)
7.3.2 Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027)
7.3.3 Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2027)
7.4 Europe Drugs for Non-small Cell Lung Cancer Market Size by Country
7.4.1 Europe Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021)
7.4.2 Europe Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size (2016-2027)
8.2 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Type
8.2.1 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2027)
8.3 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Application
8.3.1 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2027)
8.4 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Region
8.4.1 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Drugs for Non-small Cell Lung Cancer Market Size (2016-2027)
9.2 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Type
9.2.1 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021)
9.2.2 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027)
9.2.3 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2027)
9.3 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Application
9.3.1 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021)
9.3.2 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027)
9.3.3 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2027)
9.4 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Country
9.4.1 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021)
9.4.2 Latin America Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size (2016-2027)
10.2 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Type
10.2.1 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2027)
10.3 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Application
10.3.1 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2027)
10.4 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Country
10.4.1 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.2.5 GlaxoSmithKline Recent Development
11.3 Menarini
11.3.1 Menarini Company Details
11.3.2 Menarini Business Overview
11.3.3 Menarini Drugs for Non-small Cell Lung Cancer Introduction
11.3.4 Menarini Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.3.5 Menarini Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Introduction
11.4.4 Sanofi Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.4.5 Sanofi Recent Development
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Details
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.5.5 Ziopharm Oncology Recent Development
11.6 Alchemia
11.6.1 Alchemia Company Details
11.6.2 Alchemia Business Overview
11.6.3 Alchemia Drugs for Non-small Cell Lung Cancer Introduction
11.6.4 Alchemia Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.6.5 Alchemia Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Drugs for Non-small Cell Lung Cancer Introduction
11.7.4 Amgen Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.7.5 Amgen Recent Development
11.8 Apotex
11.8.1 Apotex Company Details
11.8.2 Apotex Business Overview
11.8.3 Apotex Drugs for Non-small Cell Lung Cancer Introduction
11.8.4 Apotex Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.8.5 Apotex Recent Development
11.9 BioMarin Pharmaceutical
11.9.1 BioMarin Pharmaceutical Company Details
11.9.2 BioMarin Pharmaceutical Business Overview
11.9.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Introduction
11.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.9.5 BioMarin Pharmaceutical Recent Development
11.10 CellAct Pharma
11.10.1 CellAct Pharma Company Details
11.10.2 CellAct Pharma Business Overview
11.10.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Introduction
11.10.4 CellAct Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.10.5 CellAct Pharma Recent Development
11.11 Cerulean Pharma
11.11.1 Cerulean Pharma Company Details
11.11.2 Cerulean Pharma Business Overview
11.11.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Introduction
11.11.4 Cerulean Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.11.5 Cerulean Pharma Recent Development
11.12 Cipla
11.12.1 Cipla Company Details
11.12.2 Cipla Business Overview
11.12.3 Cipla Drugs for Non-small Cell Lung Cancer Introduction
11.12.4 Cipla Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.12.5 Cipla Recent Development
11.13 Cornerstone Pharmaceuticals
11.13.1 Cornerstone Pharmaceuticals Company Details
11.13.2 Cornerstone Pharmaceuticals Business Overview
11.13.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
11.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.13.5 Cornerstone Pharmaceuticals Recent Development
11.14 Curis
11.14.1 Curis Company Details
11.14.2 Curis Business Overview
11.14.3 Curis Drugs for Non-small Cell Lung Cancer Introduction
11.14.4 Curis Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.14.5 Curis Recent Development
11.15 CytRx
11.15.1 CytRx Company Details
11.15.2 CytRx Business Overview
11.15.3 CytRx Drugs for Non-small Cell Lung Cancer Introduction
11.15.4 CytRx Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.15.5 CytRx Recent Development
11.16 Eli Lilly
11.16.1 Eli Lilly Company Details
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Introduction
11.16.4 Eli Lilly Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.16.5 Eli Lilly Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Drugs for Non-small Cell Lung Cancer Introduction
11.17.4 Exelixis Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.17.5 Exelixis Recent Development
11.18 Fresenius Kabi
11.18.1 Fresenius Kabi Company Details
11.18.2 Fresenius Kabi Business Overview
11.18.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Introduction
11.18.4 Fresenius Kabi Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.18.5 Fresenius Kabi Recent Development
11.18 Genentech
11.25.1 Genentech Company Details
11.25.2 Genentech Business Overview
11.25.3 Genentech Drugs for Non-small Cell Lung Cancer Introduction
11.25.4 Genentech Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.25.5 Genentech Recent Development
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Details
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.20.5 Hikma Pharmaceuticals Recent Development
11.21 Hospira
11.21.1 Hospira Company Details
11.21.2 Hospira Business Overview
11.21.3 Hospira Drugs for Non-small Cell Lung Cancer Introduction
11.21.4 Hospira Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.21.5 Hospira Recent Development
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Details
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
11.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.22.5 Intas Pharmaceuticals Recent Development
11.23 Karyopharm Therapeutics
11.23.1 Karyopharm Therapeutics Company Details
11.23.2 Karyopharm Therapeutics Business Overview
11.23.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Introduction
11.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.23.5 Karyopharm Therapeutics Recent Development
11.24 Kyowa Hakko Kirin
11.24.1 Kyowa Hakko Kirin Company Details
11.24.2 Kyowa Hakko Kirin Business Overview
11.24.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Introduction
11.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.24.5 Kyowa Hakko Kirin Recent Development
11.25 Ligand Pharmaceuticals
11.25.1 Ligand Pharmaceuticals Company Details
11.25.2 Ligand Pharmaceuticals Business Overview
11.25.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
11.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
11.25.5 Ligand Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Drugs for Non-small Cell Lung Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Radiofrequency Ablation (RFA)
Table 3. Key Players of Radiation Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Targeted Therapies
Table 6. Key Players of Immunotherapy
Table 7. Global Drugs for Non-small Cell Lung Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Drugs for Non-small Cell Lung Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Drugs for Non-small Cell Lung Cancer Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2016-2021)
Table 11. Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2022-2027)
Table 13. Drugs for Non-small Cell Lung Cancer Market Trends
Table 14. Drugs for Non-small Cell Lung Cancer Market Drivers
Table 15. Drugs for Non-small Cell Lung Cancer Market Challenges
Table 16. Drugs for Non-small Cell Lung Cancer Market Restraints
Table 17. Global Drugs for Non-small Cell Lung Cancer Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Drugs for Non-small Cell Lung Cancer Market Share by Players (2016-2021)
Table 19. Global Top Drugs for Non-small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Non-small Cell Lung Cancer as of 2020)
Table 20. Ranking of Global Top Drugs for Non-small Cell Lung Cancer Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Drugs for Non-small Cell Lung Cancer Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Drugs for Non-small Cell Lung Cancer Product Solution and Service
Table 24. Date of Enter into Drugs for Non-small Cell Lung Cancer Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type (2016-2021)
Table 28. Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Drugs for Non-small Cell Lung Cancer Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Application (2016-2021)
Table 32. Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product
Table 67. Bristol-Myers Squibb Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Development
Table 69. GlaxoSmithKline Company Details
Table 70. GlaxoSmithKline Business Overview
Table 71. GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product
Table 72. GlaxoSmithKline Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 73. GlaxoSmithKline Recent Development
Table 74. Menarini Company Details
Table 75. Menarini Business Overview
Table 76. Menarini Drugs for Non-small Cell Lung Cancer Product
Table 77. Menarini Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 78. Menarini Recent Development
Table 79. Sanofi Company Details
Table 80. Sanofi Business Overview
Table 81. Sanofi Drugs for Non-small Cell Lung Cancer Product
Table 82. Sanofi Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 83. Sanofi Recent Development
Table 84. Ziopharm Oncology Company Details
Table 85. Ziopharm Oncology Business Overview
Table 86. Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product
Table 87. Ziopharm Oncology Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 88. Ziopharm Oncology Recent Development
Table 89. Alchemia Company Details
Table 90. Alchemia Business Overview
Table 91. Alchemia Drugs for Non-small Cell Lung Cancer Product
Table 92. Alchemia Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 93. Alchemia Recent Development
Table 94. Amgen Company Details
Table 95. Amgen Business Overview
Table 96. Amgen Drugs for Non-small Cell Lung Cancer Product
Table 97. Amgen Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 98. Amgen Recent Development
Table 99. Apotex Company Details
Table 100. Apotex Business Overview
Table 101. Apotex Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 102. Apotex Recent Development
Table 103. BioMarin Pharmaceutical Company Details
Table 104. BioMarin Pharmaceutical Business Overview
Table 105. BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product
Table 106. BioMarin Pharmaceutical Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 107. BioMarin Pharmaceutical Recent Development
Table 108. CellAct Pharma Company Details
Table 109. CellAct Pharma Business Overview
Table 110. CellAct Pharma Drugs for Non-small Cell Lung Cancer Product
Table 111. CellAct Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 112. CellAct Pharma Recent Development
Table 113. Cerulean Pharma Company Details
Table 114. Cerulean Pharma Business Overview
Table 115. Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product
Table 116. Cerulean Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 117. Cerulean Pharma Recent Development
Table 118. Cipla Company Details
Table 119. Cipla Business Overview
Table 120. Cipla Drugs for Non-small Cell Lung Cancer Product
Table 121. Cipla Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 122. Cipla Recent Development
Table 123. Cornerstone Pharmaceuticals Company Details
Table 124. Cornerstone Pharmaceuticals Business Overview
Table 125. Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product
Table 126. Cornerstone Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 127. Cornerstone Pharmaceuticals Recent Development
Table 128. Curis Company Details
Table 129. Curis Business Overview
Table 130. Curis Drugs for Non-small Cell Lung Cancer Product
Table 131. Curis Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 132. Curis Recent Development
Table 133. CytRx Company Details
Table 134. CytRx Business Overview
Table 135. CytRx Drugs for Non-small Cell Lung Cancer Product
Table 136. CytRx Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 137. CytRx Recent Development
Table 138. Eli Lilly Company Details
Table 139. Eli Lilly Business Overview
Table 140. Eli Lilly Drugs for Non-small Cell Lung Cancer Product
Table 141. Eli Lilly Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 142. Eli Lilly Recent Development
Table 143. Exelixis Company Details
Table 144. Exelixis Business Overview
Table 145. Exelixis Drugs for Non-small Cell Lung Cancer Product
Table 146. Exelixis Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 147. Exelixis Recent Development
Table 148. Fresenius Kabi Company Details
Table 149. Fresenius Kabi Business Overview
Table 150. Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product
Table 151. Fresenius Kabi Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 152. Fresenius Kabi Recent Development
Table 153. Genentech Company Details
Table 154. Genentech Business Overview
Table 155. Genentech Drugs for Non-small Cell Lung Cancer Product
Table 156. Genentech Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 157. Genentech Recent Development
Table 158. Hikma Pharmaceuticals Company Details
Table 159. Hikma Pharmaceuticals Business Overview
Table 160. Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product
Table 161. Hikma Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 162. Hikma Pharmaceuticals Recent Development
Table 163. Hospira Company Details
Table 164. Hospira Business Overview
Table 165. Hospira Drugs for Non-small Cell Lung Cancer Product
Table 166. Hospira Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 167. Hospira Recent Development
Table 168. Intas Pharmaceuticals Company Details
Table 169. Intas Pharmaceuticals Business Overview
Table 170. Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product
Table 171. Intas Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 172. Intas Pharmaceuticals Recent Development
Table 173. Karyopharm Therapeutics Company Details
Table 174. Karyopharm Therapeutics Business Overview
Table 175. Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product
Table 176. Karyopharm Therapeutics Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 177. Karyopharm Therapeutics Recent Development
Table 178. Kyowa Hakko Kirin Company Details
Table 179. Kyowa Hakko Kirin Business Overview
Table 180. Kyowa Hakko Kirin Drugs for Non-small Cell Lung CancerProduct
Table 181. Kyowa Hakko Kirin Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 182. Kyowa Hakko Kirin Recent Development
Table 183. Ligand Pharmaceuticals Company Details
Table 184. Ligand Pharmaceuticals Business Overview
Table 185. Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product
Table 186. Ligand Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2016-2021) & (US$ Million)
Table 187. Ligand Pharmaceuticals Recent Development
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Non-small Cell Lung Cancer Market Share by Type: 2020 VS 2027
Figure 2. Radiofrequency Ablation (RFA) Features
Figure 3. Radiation Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Targeted Therapies Features
Figure 6. Immunotherapy Features
Figure 7. Global Drugs for Non-small Cell Lung Cancer Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Other Case Studies
Figure 11. Drugs for Non-small Cell Lung Cancer Report Years Considered
Figure 12. Global Drugs for Non-small Cell Lung Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Drugs for Non-small Cell Lung Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions: 2020 VS 2027
Figure 15. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2022-2027)
Figure 16. Global Drugs for Non-small Cell Lung Cancer Market Share by Players in 2020
Figure 17. Global Top Drugs for Non-small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Non-small Cell Lung Cancer as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Drugs for Non-small Cell Lung Cancer Revenue in 2020
Figure 19. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type (2016-2021)
Figure 20. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type (2022-2027)
Figure 21. North America Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Drugs for Non-small Cell Lung Cancer Market Share by Type (2016-2027)
Figure 23. North America Drugs for Non-small Cell Lung Cancer Market Share by Application (2016-2027)
Figure 24. North America Drugs for Non-small Cell Lung Cancer Market Share by Country (2016-2027)
Figure 25. United States Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Drugs for Non-small Cell Lung Cancer Market Share by Type (2016-2027)
Figure 29. Europe Drugs for Non-small Cell Lung Cancer Market Share by Application (2016-2027)
Figure 30. Europe Drugs for Non-small Cell Lung Cancer Market Share by Country (2016-2027)
Figure 31. Germany Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Drugs for Non-small Cell Lung Cancer Market Share by Region (2016-2027)
Figure 41. China Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Drugs for Non-small Cell Lung Cancer Market Share by Type (2016-2027)
Figure 49. Latin America Drugs for Non-small Cell Lung Cancer Market Share by Application (2016-2027)
Figure 50. Latin America Drugs for Non-small Cell Lung Cancer Market Share by Country (2016-2027)
Figure 51. Mexico Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Drugs for Non-small Cell Lung Cancer Market Share by Country (2016-2027)
Figure 57. Turkey Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 61. GlaxoSmithKline Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 62. Menarini Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 63. Sanofi Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 64. Ziopharm Oncology Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 65. Alchemia Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 66. Amgen Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 67. Apotex Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 68. BioMarin Pharmaceutical Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 69. CellAct Pharma Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 70. Cerulean Pharma Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 71. Cipla Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 72. Cornerstone Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 73. Curis Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 74. CytRx Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 75. Eli Lilly Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 76. Exelixis Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 77. Fresenius Kabi Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 78. Genentech Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 79. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 80. Hospira Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 81. Intas Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 82. Karyopharm Therapeutics Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 83. Kyowa Hakko Kirin Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 84. Ligand Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2016-2021)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed
世界の小細胞肺がん治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Small Cell Lung Cancer Treatment Market The global Small Cell Lung Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data…- 世界の小細胞肺がん治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Small Cell Lung Cancer Treatment Market The global Small Cell Lung Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data…
- 世界の非小細胞肺がん治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Non-small Cell Lung Cancer Therapeutics Market The global Non-small Cell Lung Cancer Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis…
- 世界の小細胞肺がん治療薬市場規模・現状・予測（2021年-2027年） Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell car…
- 世界の小細胞肺がん治療薬市場規模・現状・予測（2021年-2027年） Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell car…